The Division of Head & Neck Tumor Multimodality Treatment is a key clinical unit within the Cancer Center, providing comprehensive multidisciplinary care for a wide range of malignancies.
The Division has 71 inpatient beds and a medical and nursing team of over 80 members, including:
The department is organized into 13 medical groups, including:
Annual service volume includes:
Over the past decade, the Division has published over 600 papers in leading international journals, including The Lancet Oncology, Cell Research, International Journal of Radiation Oncology, Biology, Physics, and Radiotherapy and Oncology.
Research achievements include:
The Division is distinguished by a well-developed subspecialty structure, with major strengths in head and neck tumors, lymphoma, melanoma and soft tissue tumors, and breast cancer radiotherapy.
Established for over 20 years and led by Professors Liu Lei and Chen Nianyong, this subspecialty focuses on the diagnosis and treatment of head and neck malignancies, including nasopharyngeal, nasal and paranasal sinus, laryngeal, hypopharyngeal, oropharyngeal, oral, and salivary gland cancers.
It serves as the chair unit of multiple national and provincial academic organizations. Research outcomes have been published in leading journals such as The Lancet Oncology, Radiotherapy and Oncology, and Oral Oncology, and have been cited by the NCCN Guidelines. Its comprehensive strength ranks among the leading programs in China.
Established for nearly 20 years and led by Professor Zou Liqun, this subspecialty is recognized as a National Demonstration Unit for Standardized Diagnosis and Treatment of Lymphoma and a National Cancer Center Lymphoma Single Disease Quality Control Center.
The team has contributed to national clinical guidelines and pioneered the “sandwich” therapy for NK/T-cell lymphoma, which has been cited by the NCCN Guidelines. Clinical outcomes are aligned with international standards.
Led by Professor Jiang Yu, this subspecialty has been established for nearly 20 years and serves as the chair unit of the Skin and Soft Tissue Tumor Committee of the Sichuan Cancer Society.
A multidisciplinary approach integrates surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, and psychosocial support to provide comprehensive care for melanoma and soft tissue sarcomas.
The breast cancer radiotherapy subspecialty (led by Professor Liu Lei) and the advanced breast cancer comprehensive treatment subspecialty (led by Professors Jiang Yu and Zou Liqun) have both been established for over 20 years.
Team members hold key academic leadership roles and have contributed to national guidelines. The five-year survival rate for breast cancer patients is comparable to that of developed countries.
Established for nearly 10 years and led by Professor Wang Feng, this subspecialty focuses on individualized treatment based on molecular genetic testing.
It has introduced advanced therapies such as Tumor Treating Fields (TTF) and pioneered the combination of the postoperative STUPP regimen with TTF for high-grade glioma, achieving strong clinical outcomes and international recognition.
Established for nearly 20 years and led by Professor Jiang Yu, this subspecialty provides comprehensive psychosocial support for cancer patients and their families throughout the entire treatment process.
The team was the first internationally to report systematic research on “truth-telling” to cancer patients in China. Its work has been cited in the NCCN Guidelines for Distress Management, including studies that informed revisions to guideline thresholds.
The Division integrates radiotherapy, medical oncology, and interventional therapy to deliver multimodality, patient-centered care, supported by strong academic leadership and internationally recognized research contributions.
